Drug To Treat Canine Lymphoma Gets Fda Approval

Discussion in 'Veterinary Discussion' started by Admin, Jan 6, 2017.

By Admin on Jan 6, 2017 at 3:11 PM
  1. Admin

    Admin Administrator Staff Member

    Tanovea-CA1, from veterinary cancer therapeutics company VetDC, is expected available to veterinarians in spring 2017.
    [​IMG]

    VetDC, Inc., a veterinary cancer therapeutics company, today announced that the U.S. Food and Drug Administration’s Center for Veterinary Medicine has granted a conditional approval of Tanovea™-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs.

    “This is a significant milestone for VetDC, and we are excited to announce the first ever FDA-approved drug for canine lymphoma,” stated Steven Roy, VetDC’s president and CEO. “We look forward to introducing Tanovea-CA1 to the veterinary cancer community in the months to come.”

    Tanovea-CA1 is expected to be available to veterinarians in the spring of 2017, Roy added.

    Read more
     

Comments

Discussion in 'Veterinary Discussion' started by Admin, Jan 6, 2017.

Share This Page